Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?

Biotech giant Gilead Sciences, Inc. (GILD) has put up a steady performance in 2024 amid a volatile market. Its shares have gained 15.4% in a year against the industry’s decline of 10.8%. The stock has outperformed the sector but lagged the S&P 500 Index.Approval of new drugs, encouraging pipeline progress, positive data readouts and strong quarterly results have boosted investors’ sentiment in the past six months. GILD has also raised its annual guidance for sales and earnings, driven by growth in COVID-19 ...